Adamas Pharmaceuticals (ADMS) PT Lowered to $23 at Piper Jaffray
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Piper Jaffray analyst David Amsellem lowered the price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $23.00 (from $49.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Goldman Sachs Upgrades Plains All American (PAA) to Neutral
- Tokio Marine Holdings, Inc (8766:JP) (TKOMY) PT Lowered to JPY8,400 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
